PUBLICATIONS
"On the Use of Manufacturer Pharmaceutical Coupons: Brand Loyalty or Customer Acquisition?"
(with J. Gibbons and A. Trujillo) Forthcoming 2024, Health Services Research.
"Regulating Ethical Experimentation: Impact of the Breakthrough Therapy Designation on Drug R&D", Journal of Health Economics 94 (2024).
"Leveraging the E-commerce Footprint for the Surveillance of Healthcare Utilization"
(with J. Ni, H. Wang, and J. Zhang) Health Care Management Science 26.4 (2023): 604-625.
"Association Between Universal Health coverage and the Disease Burden of Acute Illness and Injury at the Global Level''
(With K. Hajjar, L. Lillo, D. Martinez, and N. Risko) BMC Public Health 23.1 (2023): 735.
"Does Bad Medical News Reduce Preferences for Generic Drugs?"
(With A. Ching) Journal of Marketing 88.1 (2024): 160-178. Previously titled: "Bad Medical News and the Aversion of Generic Drugs"
"Covid-19 Unemployment and Access to Statin Medications in the United States"
(with C. Alexander and D. Polsky) Frontiers of Public Health, 2023, 11:1124151, 1-13.
"Does Consumer Demand 'Pull' Scientifically Novel Drug Innovation?"
(with D. Dranove and C. Garthwaite) RAND Journal of Economics, 2022, 53(3), 590-638. SSRN version.
“Prospective Adverse Event Risk Evaluation in Clinical Trials”
(with F. Feijoo, A. Kundu, D. Martınez, and T. Matis) Health Care Management Science, 2021, 1-11.
"Rushed Innovation: Evidence from Drug Licensing"
Management Science. 2021, 67(1), 257-278. SSRN version.
"Structural Models of the Prescription Drug Market"
(with A. Ching and Q. Liu) Foundations & Trends in Marketing 2019, 13 (1), 1-76. SSRN version.
"Therapeutic Translation of Genomic Science: Opportunities and limitations of GWAS"
(with J. Lemus) Economic Dimensions of Precision and Personalized Medicine, Berndt, Goldman, Rowe Eds., University of Chicago Press, 2019. NBER Working Paper version.
"Can Emerging Markets Tilt Global Product Design? Impacts of Chinese Colorism on Hollywood Castings"
(with F. Gutierrez and J. Prieto) Marketing Science 2018, 37(3), 356-381. SSRN version.
"Market Size and Innovation: The Intermediary Role of Technology Licensing"
(with Y. Wu) Research Policy 2018, 47(5), 980-991. SSRN version.
"Use of Online Recruitment Strategies in a Randomized Trial of Cancer Survivors"
(with S. Juraschek et al.) Clinical Trials 2017, 15(2), 130-138.
"Renegociación de Contratos de Obras Públicas: Evidencia de Chile"
(with E. Engel, R. Fischer, and A. Galetovic) Estudios Publicos 113 (2009), Centro de Estudios Publicos.
"La Renegociación de Contratos de Obras Públicas y la Nueva Ley"
(with E. Engel, R. Fischer, and A. Galetovic) Puntos de Referencia 297 (2008), Centro de Estudios Publicos.
WORKING PAPERS
"Does Transparency Hinder Drug Novelty? Evidence from Large Pharmaceutical Firms"
(with R. Shah and H. Tyagi) 2023, R&R.
"Are Female-led Trials Safer?"
2023, under review.
"The Interplay of Online and Offline Pharmacies: Evidence from a Large Pricing Experiment"
(with C. Liu and J. Ni) 2023, under review.
IN PROGRESS
"Have Commercial Frictions Slowed Down Biosimilar Penetration?"
(with K. Anderson and J. Levy)
"Does Brand Equity Affect Perceived Drug Safety?"
"Did the NDM-1 Superbug Encourage the Use of `Last Resort' Antibiotics?"
(with S. Agrawal, C. Chatterjee, and E. Klein)